Cancer – ALTE1621: Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure: a Phase 2b Randomized Placebo-Controlled Trial
Condition or Therapy:
Cancer and Blood Disorders
Study Number: ALTE1621
What is the goal of this study?
Researchers want to know how well low-dose carvedilol works in preventing heart failure in cancer survivors exposed to high dose anthracyclines.
Who can join the study?
This study may be a good fit for children and young adults who:
- are any age,
- weigh greater than 40 kg (approx. 88 lbs),
- had a cancer diagnosis under the age of 22, and
- have completed cancer treatment.
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106 or email the study coordinator.